{
    "clinical_study": {
        "@rank": "168288", 
        "acronym": "PG-OCT", 
        "arm_group": {
            "arm_group_label": "Drug application", 
            "arm_group_type": "Experimental", 
            "description": "4 treatment periods. On each period one of the following interventions"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effect of the organic cation transporter OCT1\n      polymorphisms on the pharmacokinetics of several drugs in order to explain efficacy and\n      adverse effects."
        }, 
        "brief_title": "Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Drug Metabolism", 
            "Membrane Transport"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent obtained prior to study entry including informed consent for\n             molecular genetic analysis concerning candidate genes relevant for pharmacokinetics\n             and pharmacodynamics of the study medication.\n\n          2. Both genders (male and female), as far as feasible, in each of the 3 OCT1 genotype\n             groups, an equal proportion of males and females will be included.\n\n          3. Healthy adults aged \u226518 to < 50 years\n\n          4. Body weight not less than 48 kg and body mass index (BMI) not less than 17 kg/m\u00b2 and\n             not greater than 32 kg/m\u00b2.\n\n          5. Willingness to meet the study instructions and to co-operate with the study personal\n\n          6. No clinically relevant pathological findings in any of the investigations at the\n             screening visit. Minor deviations of laboratory values from the normal range may be\n             accepted, if judged by the investigator to have no clinical relevance\n\n          7. Systolic blood pressure \u2264 140 mmHg and \u2265 100 mmHg, diastolic blood pressure \u2264 90 mmHg\n             and \u2265 60 mmHg and heart rate \u2264 90 bpm and \u2265 50 bpm at screening visit\n\n          8. Female subjects will only be included if they express their willingness not to become\n             pregnant during the entire study period by practicing abstinence or reliable methods\n             of contraception as specified in the respective protocol section.\n\n          9. Nonsmokers\n\n        Exclusion Criteria:\n\n          1. Unwillingness or inability to give informed consent\n\n          2. Involvement in the planning and conduct of the study (applies to staff directly\n             employed at the study site / department)\n\n          3. Participation in a clinical study or use of any other investigational or\n             non-registered drug or vaccine during the study period or within 30 days preceding\n             the first dose of study drugs.\n\n          4. Blood, plasma or thrombocyte donation during the last 15 days prior to application of\n             the test drugs.\n\n          5. Any planned surgical treatment during the last 14 days prior and 14 days after the\n             application of the test drugs.\n\n          6. Known pregnancy or lactation period\n\n          7. Any relevant pathological findings in any of the investigations at the screening\n             visit including significant abnormalities as result of the\n             medical-screening-laboratory-analysis, especially of the liver and kidney related\n             parameters unless judged as medically irrelevant.\n\n          8. QTcF > 450 ms in screening ECG\n\n          9. Systolic blood pressure > 140 mmHg and < 100 mmHg, diastolic blood pressure > 90 mmHg\n             and < 60 mmHg and heart rate > 90 bpm and < 50 bpm pre-dose at treatment period 4\n             (Amitriptyline)\n\n         10. Any disease affecting liver or kidney or impairment of the liver or kidney-function\n\n         11. Any cardiovascular disease\n\n         12. Moderate to severe hypertension requiring medication therapy\n\n         13. Bronchogenic asthma requiring constant drug treatment (stages 2 to 4 asthma)\n\n         14. Diabetes mellitus, hyperthyroidism, hypothyroidism\n\n         15. Glaucoma\n\n         16. Symptomatic prostatic hyperplasia\n\n         17. Any medical constellation that increases risk of bleeding, including chronic\n             treatment with NSAID or COX-2 inhibitors\n\n         18. History of alcohol and/or drug abuse and/or any abusive use of medicaments and/or\n             positive drug screen\n\n         19. History of any psychiatric or neurologic disorder. If there are any doubts at the\n             screening visit on whether a person is suffering from a depression or not he or she\n             will be excluded from the study or examined by a psychiatrist for clarification\n             before inclusion.\n\n         20. Any major gastrointestinal disease and any gastrointestinal disorder that is expected\n             to significantly interfere with the pharmacokinetics of the study drug\n\n         21. Gastrointestinal surgery which may interfere with the pharmacokinetics of the study\n             drug (except appendectomy or herniotomy)\n\n         22. Taking any medication within 7 days before or during the trial with the following\n             exceptions: Oral contraceptive drug used will be documented but will not be an\n             exclusion criterion. Other medication might be allowed on single case basis if\n             considered necessary for the subject's safety and well-being and if interactions with\n             the study medication are judged as irrelevant.\n\n         23. Any other findings that could compromise the safety of the participant or the quality\n             of the study-results\n\n         24. Any known hypersensitivity or allergic reactions to any of the tested drugs\n\n         25. History of severe hypersensitivity reactions and anaphylaxis\n\n         26. Any other clinically significant diseases as judged by the investigator\n\n         27. Body temperature > 37.5\u00b0C prior to drug application\n\n         28. Known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C (no laboratory\n             diagnostics concerning these diseases will be performed within the present study)\n\n         29. Inability or unwillingness to avoid any intake of alcohol from 48 h prior to until 72\n             hours after Investigational Medicinal Product (IMP) application application\n\n         30. Pregnancy (positive pregnancy test performed prior to drug administration)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054299", 
            "org_study_id": "PG-OCT", 
            "secondary_id": "2012-003546-33"
        }, 
        "intervention": [
            {
                "arm_group_label": "Drug application", 
                "description": "Amitriptyline: 25 mg, single oral application", 
                "intervention_name": "Drug application Amitriptyline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Drug application", 
                "description": "Desvenlafaxine: 50 mg, single oral application", 
                "intervention_name": "Drug application Desvenlafaxine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Drug application", 
                "description": "Sumatriptan: 50 mg, single oral application", 
                "intervention_name": "Drug application Sumatriptan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Drug application", 
                "description": "Proguanil: 200mg, single oral application", 
                "intervention_name": "Drug application Proguanil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amitriptyline", 
                "O-desmethylvenlafaxine", 
                "Amitriptyline, perphenazine drug combination", 
                "Sumatriptan", 
                "Proguanil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "contact": {
                "email": "johannes.matthaei@med.uni-goettingen.de", 
                "last_name": "Johannes Matthaei, MD", 
                "phone": "00495513922288"
            }, 
            "facility": {
                "address": {
                    "city": "Goettingen", 
                    "country": "Germany", 
                    "zip": "37075"
                }, 
                "name": "Department of Clinical Pharmacology, University Medical Center Goettingen"
            }, 
            "investigator": [
                {
                    "last_name": "Juergen Brockmoeller, Prof.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Johannes Matthaei, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Frank Faltraco, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Markus Schirmer, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Daniel Sehrt, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effects of Genetic Polymorphisms in the Organic Cation Transporter OCT1 on Cellular Uptake and Metabolism of Antidepressants and Other Organic Cationic Drugs", 
        "overall_contact": {
            "email": "jbrockm@gwdg.de", 
            "last_name": "Juergen Brockmoeller, Prof.", 
            "phone": "0049551395770"
        }, 
        "overall_official": {
            "affiliation": "University Medical Center Goettingen", 
            "last_name": "Juergen Brockmoeller, Prof.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the plasma concentration-time curve (AUC) of the investigational drugs", 
            "safety_issue": "No", 
            "time_frame": "up to 60 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054299"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Medical Center Goettingen", 
            "investigator_full_name": "Johannes Matthaei", 
            "investigator_title": "Sub-investigator, Principal investigator is Prof. Juergen Brockmoeller", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total clearance, Cmax, Tmax, Mean AbsorptionTime, Alpha and Beta half-lives, Mean Residence Time (MRT) and Volume of distribution of the investigated drugs and their metabolites", 
                "safety_issue": "No", 
                "time_frame": "up to 60 hours"
            }, 
            {
                "measure": "Dry mouth, fatigue, nausea, headache, vertigo, tinnitus, chills,  anxiety and difficulties to read on Visual Analog Scales.", 
                "safety_issue": "No", 
                "time_frame": "up to 60 hours"
            }, 
            {
                "measure": "Sedation on Stanford sedation scale", 
                "safety_issue": "No", 
                "time_frame": "up to 60 hours"
            }, 
            {
                "measure": "Pupil diameter, latency, diameter at maximal constriction, amplitude and time for 33% recovery of initial pupil diameter measured by pupillometrie", 
                "safety_issue": "No", 
                "time_frame": "up to 60 hours"
            }, 
            {
                "measure": "Genetic variants in OCT1, CYP2C19, CYP2D6 and MAO A", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "source": "University Medical Center Goettingen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Medical Center Goettingen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}